Clinical Trials

18 results for Prostate Cancer

Local Treatment With Radical Prostatectomy (RP) for Newly-diagnosed Metastatic Prostate Cancer (mPCa).

  • Condition: Prostatic Neoplasms, Neoplasm Metastasis
  • Intervention:
  • Study ID: NCT02138721
View Trial

Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men With Advanced Prostate Cancer (IRONMAN)

  • Condition: Prostate Cancer
  • Intervention: Other: Standard of Care
  • Study ID: NCT03151629
View Trial

Cognitive Effects of Androgen Receptor (AR) Directed Therapies for Advanced Prostate Cancer

  • Condition: Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer, Hormone-Refractory Prostate Cancer
  • Intervention: Biological: GnRH agonist/antagonist, Drug: Prednisone, Drug: Abiraterone Acetate, Drug: Enzalutamide
  • Study ID: NCT03016741
View Trial

Phase II Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations (TRIUMPH)

  • Condition: Prostate Cancer Metastatic
  • Intervention: Drug: Rucaparib
  • Study ID: NCT03413995
View Trial

Bone Response After Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients With Hormone Sensitive Metastatic Bone Disease: a Prospective, Phase II, Randomized, Multicenter Study

  • Condition: Prostate Cancer, Bone Metastases
  • Intervention: Drug: Zoledronic Acid, Drug: Enzalutamide
  • Study ID: NCT03336983
View Trial

A Phase 2 Trial of Radium Ra 223 Dichloride in Combination With Androgen Deprivation Therapy and Stereotactic Body Radiation Therapy for Patients With Oligometastatic Castration Sensitive Prostate Cancer

  • Condition: Prostate Adenocarcinoma
  • Intervention: Drug: Leuprolide Acetate, Drug: Goserelin Acetate, Radiation: Stereotactic Body Radiation Therapy, Radiation: Radium Ra 223 Dichloride, Other: Laboratory Biomarker Analysis
  • Study ID: NCT03361735
View Trial

SAABR: Single-Arm Phase II Study of Abiraterone Acetate + Atezolizumab + Lupron and Stereotactic Body Radiotherapy (SBRT) to the Prostate in Men With Newly Diagnosed Hormone-sensitive Metastatic Prostate Cancer

  • Condition: Metastatic Prostate Cancer
  • Intervention: Drug: Atezolizumab, Drug: Abiraterone, Drug: Prednisone, Drug: Lupron, Radiation: Stereotactic Body Radiotherapy (SBRT)
  • Study ID: NCT04262154
View Trial

A Randomized Phase II Trial to Evaluate the Antitumor Activity of Enzalutamide and Talazoparib (PF-06944076) for the Treatment of Metastatic Hormone-naïve Prostate Cancer

  • Condition: Metastatic Prostate Cancer
  • Study ID: NCT04332744
View Trial

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Re

  • Condition: Metastatic Castrate Sensitive Prostate Cancer
  • Study ID: NCT04497844
View Trial

Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients - a GETUG-AFU Phase III Randomized Controlled Trial

  • Condition: Oligometastatic Hormone Sensitive Prostate Cancer
  • Study ID: NCT04115007
View Trial

A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, With an Observational Fol

  • Condition: Prostatic Neoplasms
  • Study ID: NCT04557059
View Trial

Phase 4 Study of Exploring Circulating Tumor DNA (ctDNA) of Metastatic Castration-sensitive Prostate Cancer (mCSPC) Patients Receiving Apalutamide in Japan

  • Condition: Metastatic Castration-sensitive Prostate Cancer
  • Study ID: NCT04601441
View Trial


  • Condition: Prostate Cancer
  • Study ID: NCT04821622
View Trial

An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

  • Condition: Prostatic Neoplasms
  • Study ID: NCT04720157
View Trial

A Phase 1, Open-Label, Single-Cohort Safety and Tolerability Study of Relugolix in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Castration-Sensitive Prostate Cancer or Metastatic Castration-Resistant Prostate Cancer Being

  • Condition: Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer
  • Study ID: NCT04666129
View Trial

Open-label Study of Androgen Receptor Inhibition With dArolutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Men With Metastatic Hormone-Sensitive Prostate Cancer Using an External Control Arm

  • Condition: Metastatic Hormone-sensitive Prostate Cancer
  • Study ID: NCT05059236
View Trial

CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer

  • Condition: Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Aceta
  • Study ID: NCT05288166
View Trial

A 2-stage, Lead-in and Randomized, Phase 2, Open-label Study of Darolutamide Versus Enzalutamide as Monotherapy on Testosterone Levels Change in Men With Hormone-Naïve Prostate Cancer

  • Condition: Biochemically Recurrent Prostate Cancer
  • Study ID: NCT05526248
View Trial